Sat.May 28, 2022 - Fri.Jun 03, 2022

article thumbnail

Patient centricity in drug innovation and packaging design to take centre stage at Connect in Pharma in Geneva this September

Drug Discovery Today

Talk from Roche engineer Tiffany McIntire will highlightopportunities for the pharma sector to reinvent packaging to bemore focused on patient needs in areas such as medication takenorally

Packaging 100
article thumbnail

The Case for Data Unity, Sharing, and Usability

Drug Channels

Today’s guest post comes from Bonnie Briggs, Associate Director of Clinical Effectiveness at Wolters Kluwer, Health. Bonnie describes how pharmaceutical care would benefit from standard medical record identification. She then discusses the practical issues behind implementing and adopting such a system. To learn more, download the Wolters Kluwer free ebook: Drug Data Unity: Realistic and Idealistic Futures for Information Exchange.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New patent expiration for Horizon drug VIMOVO

Drug Patent Watch

Annual Drug Patent Expirations for VIMOVO Vimovo is a drug marketed by Horizon and is included in one NDA. It is available from one supplier. There are nine patents protecting…. The post New patent expiration for Horizon drug VIMOVO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 65
article thumbnail

SARS-CoV-2 Protease Inhibitors: An Attractive Approach for Treating COVID-19

PerkinElmer

The current SARS-CoV-2 pandemic has highlighted the substantial threat posed by pathogenic coronaviruses to humans. To date, over six million people have died from COVID-19 across the globe and more than 500 million cases have been reported. 1 Although effective COVID-19 vaccines have been developed, variants of SARS-CoV-2 have already emerged for which vaccines are less effective, and many people remain unvaccinated due to certain medical conditions, personal choice, or global access challenges

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

The Current issue of “The view from here” is concerned with Cancer

Drug Discovery Today

The topic of this month’s newsletter from Drug Discovery Today is “Cancer”.

Drugs 113
article thumbnail

Drug Channels News Roundup, May 2022: SaveonSP Sued, RIP Medicaid Accumulator Rule, CVS/ABC Deal, Buy-and-Bill Profits, and Aetna’s Prior Authorizations

Drug Channels

Summer unofficially began over the weekend. Let’s turn up the heat with these sizzling news bites straight from the Drug Channels grill: SaveonSP gets sued Thoughts on the Medicaid accumulator rule opinion CVS buys AmerisourceBergen’s specialty pharmacy Fresh data on hospitals’ cancer drug profiteering Plus, Dr. Glaucomflecken explains Aetna’s prior authorization policies.

More Trending

article thumbnail

FDA Launches New Dietary Supplement Education Initiative for Consumers, Educators, and Healthcare Professionals

The Pharma Data

Today, the U.S. Food and Drug Administration launched a new initiative, Supplement Your Knowledge , to help educate, inform, and broaden consumer, educator and healthcare professional understanding of dietary supplements. More than half of all Americans take dietary supplements daily or on occasion. Today’s Supplement Your Knowledge resources will provide reliable information about the potential benefits and risks associated with dietary supplements, such as vitamins, minerals, and herbs, they m

FDA 52
article thumbnail

Warp Speed, Vaccines, and Agile Practices

EG Life Sciences

In his last talk at Bio-IT World, Dr. Terry Barnhart spoke of the potential of Agile practices in pharmaceutical innovation. At the most recent Bio-IT World conference , Barnhart shows how Agile practices not only bring products to market faster – they also save lives. As we have discussed in previous Lean Coffees about the intersections between Agile practices and Biopharma, organizations can incorporate Agile practices without using the "Agile" label or terminology , and a major example is Ope

Vaccine 52
article thumbnail

Accelerating digital transformation: Taking the lead on data and process standardization

The Connected Lab

Digital transformation is revolutionizing pharmaceutical research and manufacturing. Driven by technologies such as advanced automation, smart sensors, artificial intelligence and machine learning, digital transformation provides new opportunities for organizations to streamline workflows, boost productivity and improve quality throughout the value chain.

article thumbnail

New patent for Clarus drug JATENZO

Drug Patent Watch

Annual Drug Patent Expirations for JATENZO Jatenzo is a drug marketed by Clarus and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Clarus drug JATENZO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

The Pharma Data

GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.

Vaccine 52
article thumbnail

How Lorenzo Bomba is using rare genetic variants to understand blood metabolites

The Open Targets Blog

Lorenzo Bomba was a postdoctoral fellow in the Soranzo group, which uses large-scale genomic analysis to study the human variation linked to cardiometabolic traits and diseases. He recently published the results of an Open Targets project  which found new associations between genes and blood metabolites in the American Journal of Human Genetics.

Disease 52
article thumbnail

What are analytical method development services?

Altus Drug Development

From natural health products to life-saving medicines, all pharmaceutical products must undergo an analytical method development process. Through analytical method development, validation, and transfer, drug development and manufacturing are kept safe, efficient, and compliant with the law. What is analytical method development? Analytical method development is the creation of a set of experimental conditions to perform analytical procedures in chemical samples.

article thumbnail

Which pharmaceutical companies have the most SPCs in Slovakia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

The Pharma Data

New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo ® with Bristol Myers Squibb’s technologies and oncology drug development expertise. Immatics to receive upfront payment of $60 million and additional milestone payments of up to $700 million per program plus tiered royalty payments of up to low double-digit percentages on net product sales across multiple programs under the new collaboration.

article thumbnail

R&D Partnering Testimonials from Bayer, Oldcastle and Joyn Bio

Translation

Companies invest more than $2 trillion in R&D annually to stay ahead of competition, identify new products, and find new sources of revenue. These R&D efforts are fundamental to solving some of the world’s most challenging problems like combating climate change and curing diseases. Today, 80% of companies that invest in R&D partner with outside innovators.

article thumbnail

What are value-added medicines?

Altus Drug Development

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.

article thumbnail

New patent for Eli Lilly drug OLUMIANT

Drug Patent Watch

Annual Drug Patent Expirations for OLUMIANT Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are…. The post New patent for Eli Lilly drug OLUMIANT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19

The Pharma Data

The Phase 3 ACTIV-1 Immune Modulators study was sponsored by the National Institutes of Health as part of the ACTIV initiative. Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19. Safety profile of Orencia remained consistent, with no new safety signals reported. Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-1) Immune Modulators clinical tri

article thumbnail

Can tailored text message quit support programs help close the gap in treatment outcomes experienced by low socioeconomic smokers in Australia?

National Drug & Alcohol Research Centre Blog

Dr Ryan Courtney and Jack Anderson Tobacco smoking is the leading preventable cause of death, globally. In 2019, approximately 14% of Australians aged 14 years or older were current smokers. That’s approximately 2.9 million Australians. On World No Tobacco Day , Dr. Ryan Courtney and his team would like to highlight the importance of quit smoking research in low socioeconomic populations and provide details on an exciting new technology-based quit support study that begins recruitment in June 20

article thumbnail

What value-added medicines might bring to society

Altus Drug Development

Everyone is interested in having access to the best healthcare available. However, many patients end up having to face the fact that many treatments are unfeasible, too expensive, or potentially counter-conducive. Knowledge of issues within the healthcare system is not unknown to those in charge. However, dealing with them often requires making structural changes many industry players are not willing or able to perform.

article thumbnail

Which pharmaceutical companies have the most suspension dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most suspension dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suspension dosed drugs…. The post Which pharmaceutical companies have the most suspension dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

The Pharma Data

Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for specific targeting of tumor cells without binding to healthy cells This partnership allows Boehringer Ingelheim to strengthen its tumor cell-directed Antibody-Drug Conjugate (ADC) and immune cell-targeted (T-cell engager) portfolio.

article thumbnail

Search

Broad Institute

Search By admin June 3, 2022 Breadcrumb Home Search Show results from www.broadinstitute.org intranet.broadinstitute.

52
article thumbnail

Challenges and opportunities in oral formulation development

Altus Drug Development

Thanks to oral formulation, many drugs crucial for the health and well-being of millions of people can be administered and save countless lives. The field of drug formulation is in a constant state of innovation, creating a plethora of challenges to overcome, but also opening up a world of opportunities. What is oral formulation? Oral formulation is the development and manufacturing of pharmaceuticals designed for oral delivery.

article thumbnail

New patent for Endo Ventures drug EPHEDRINE SULFATE

Drug Patent Watch

Annual Drug Patent Expirations for EPHEDRINE+SULFATE Ephedrine Sulfate is a drug marketed by Akorn, Amneal, Dr Reddys Labs Ltd, Endo Ventures, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma,…. The post New patent for Endo Ventures drug EPHEDRINE SULFATE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

The Pharma Data

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Dr. Ma will assume responsibility for Gilead’s Pharmaceutical Development and Manufacturing organization effective July 18, 2022.

Science 52
article thumbnail

Dobbs Would Likely Have Significant Impacts On Drug And Device Companies

Drug & Device Law

Despite our use of plural pronouns, almost all of our posts come from a single author. We occasionally have guest posts by multiple authors or a post that pairs one of us with a subject matter expert. For this post, however, all seven authors of the Blog are joining together. We are just simple defense hacks writing about product liability law and some other things that matter to medical product manufacturers.

article thumbnail

Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa

The Pharma Data

Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed with SCD that is designed to work even with intermittent internet access, supporting early and effective care Partnership also broadens knowledge of disease burden and clinical pathway, enabling policy makers to include SCD as healthcare priority Hydroxyurea, current global standard of care for SCD, will

Disease 52
article thumbnail

AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic

The Pharma Data

AstraZeneca’s Chief Executive Officer, Pascal Soriot, today received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022. Leif Johansson, AstraZeneca Chair, said: “I am delighted for Pascal, his family, and all those at AstraZeneca with this recognition of his remarkable contribution to UK life sciences and response to the pandemic.

Science 52
article thumbnail

Blocking enzyme could hold the key to preventing, treating severe COVID-19

The Pharma Data

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Scientists who have long studied this molecule’s functions in bacterial infections traced development of extensive lung damage in infected mice to heightened levels of the enzyme triggered by the invading SARS-CoV-2 virus.

article thumbnail

FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

The Pharma Data

The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A, a rare and life-threatening bleeding disorder, based on data from the pivotal XTEND-1 P hase 3 stud y. Sanofi and Sobi ® collaborate on the development and commercialization of efanesoctocog alfa.

article thumbnail

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

The Pharma Data

Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints. Zuranolone 50 mg was generally well-tolerated and demonstrated a safety profile consistent with prior studies. Postpartum depression is one of the most common medical complications during and after pregnancy impacting approximately 1 in 8 women annually in the U.S.